Stefan Kubicka
Overview
Explore the profile of Stefan Kubicka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
3297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, et al.
Cancer Immunol Res
. 2024 Nov;
13(2):200-209.
PMID: 39527097
Anti-PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma, but long-term survival remains limited. In this study, we report extended follow-up data from...
2.
Seufferlein T, Lausser L, Stein A, Arnold D, Prager G, Kasper-Virchow S, et al.
PLoS One
. 2024 Jun;
19(6):e0304324.
PMID: 38875244
Background: Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance...
3.
Kouladouros K, Schneider K, Kubicka S, Hoerner C, Hirth M
Z Gastroenterol
. 2023 Sep;
62(6):944-951.
PMID: 37751770
McKittrick-Wheelock syndrome (MKWS) is an uncommon clinical manifestation of large, villous, epithelial lesions of the distal colon and rectum. Excessive secretion of electrolyte-rich mucus from these lesions leads to secretory...
4.
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes S, Simnica D, et al.
JAMA Oncol
. 2022 Jun;
8(8):1150-1158.
PMID: 35737383
Importance: In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations. Objective: To investigate the efficacy of...
5.
Gabor J, Kreidenweiss A, Weber S, Salama M, Sulyok M, Sulyok Z, et al.
Int J Infect Dis
. 2021 Apr;
106:265-268.
PMID: 33848675
Introduction: Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-19) was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk of hydroxychloroquine interactions with co-morbidities...
6.
Gillissen A, Kubicka S
MMW Fortschr Med
. 2021 Feb;
163(3):58-65.
PMID: 33591524
No abstract available.
7.
Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin N, Kloos A, et al.
Nat Commun
. 2019 Jul;
10(1):3236.
PMID: 31324774
Virus-neutralizing antibodies are a severe obstacle in oncolytic virotherapy. Here, we present a strategy to convert this unfavorable immune response into an anticancer immunotherapy via molecular retargeting. Application of a...
8.
Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, et al.
Eur J Cancer
. 2018 Feb;
92:11-19.
PMID: 29413685
Background: Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect...
9.
Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, et al.
Cancer Res
. 2017 Nov;
78(2):475-488.
PMID: 29180478
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and disseminating cancer resistant to therapy, including checkpoint immunotherapies, and early tumor resection and (neo)adjuvant chemotherapy fails to improve a poor prognosis....
10.